Results 301 to 310 of about 108,133 (341)

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study

Diabetes, obesity and metabolism
We aimed to investigate the long‐term impact of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on thyroid function, cardiovascular health, renal outcomes and adverse events in individuals with obesity and without type 2 diabetes (T2D).
Yu-Nan Huang, Wen-Ling Liao, Jing-Yang Huang, Yu-Jung Lin, Shun-Fa Yang, Chieh-Chen Huang, Chung-Hsing Wang, P. Su   +7 more
semanticscholar   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database

Diabetes, obesity and metabolism
To evaluate the potential association between suicidality and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), as well as other medications used for obesity and diabetes, using comprehensive global data.
Tae Hyeon Kim, Kyeongmin Lee, Seoyoung Park, Hanseul Cho, Jaeyu Park, Hyesu Jo, Yejun Son, Soeun Kim, Jiseung Kang, Lee Smith, M. Rahmati, G. Fond, Laurent Boyer, D. Pizzol, Hayeon Lee, Sang Youl Rhee, Jiyoung Hwang, Hyunji Sang, D. Yon   +18 more
semanticscholar   +1 more source

Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice

Anesthesiology
This review discusses recent evidence addressing risks in patients taking glucagon-like peptide-1 receptor agonist medications and proposes a framework for perioperative management.
Adriana D. Oprea, Guillermo E. Umpierrez, BobbieJean Sweitzer, D. Hepner   +3 more
semanticscholar   +1 more source

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

The Lancet, 2006
D. Drucker, M. Nauck
semanticscholar   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) show anti‐inflammatory properties.
Aakash Desai, Jessica C Petrov, Jana G. Hashash, Harsh Patel, Bhaumik Brahmbhatt, G. Kochhar, F. Farraye   +6 more
semanticscholar   +1 more source

Periconceptional Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation

JAMA Cardiology
This Viewpoint describes the need for more studies on the best timing for dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
Sadiya S, Khan, William A, Grobman, Dhruv S, Kazi   +2 more
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly